{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:11:27Z","timestamp":1787069487464,"version":"build-2736575974"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with cardiometabolic morbidity, yet published estimates of cardiovascular comorbidities and cardiovascular risk in patients with HS vary widely.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To quantify the prevalence of cardiovascular comorbidities in individuals with HS, and to evaluate associations between HS and cardiovascular outcomes compared with individuals without HS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis is reported in accordance with the PRISMA 2020 guidelines. CINAHL, Cochrane, Embase, PubMed and Scopus were searched from inception through 16 June 2025. Eligible studies included individuals with clinician-diagnosed HS, ascertained by medical records, diagnostic codes or physician assessment, that reported cardiovascular comorbidity prevalence or association estimates. For prevalence analyses, studies reported cardiovascular comorbidity prevalence in HS cohorts; for association analyses, studies included participants with HS and a comparison group without HS. The most adjusted estimate available was preferentially selected for each study\u2013outcome pair; when adjusted estimates were unavailable, the only reported estimate was retained. Risk of bias was assessed using Joanna Briggs Institute checklists; certainty of evidence was evaluated using GRADE. Random-effects meta-analyses were used for pooled estimates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-five studies met the inclusion criteria, comprising 373 689 individuals with HS; 24 contributed prevalence data and 17 contributed association estimates. Hypertension was the most frequently reported cardiovascular comorbidity, affecting approximately one-quarter of patients, followed by coronary artery disease, cerebrovascular disease, congestive heart failure and myocardial infarction. Meta-analyses demonstrated that HS was associated with an increased risk of multiple cardiovascular outcomes compared with individuals without HS, with relative risks generally ranging from 1.3- to 1.8-fold for ischaemic or coronary heart disease, composite cardiovascular disease, myocardial infarction, heart failure, venous thromboembolism and all-cause mortality. Associations remained directionally consistent in sensitivity analyses, although substantial heterogeneity was present across most analyses. The certainty of evidence was low, reflecting the observational design of the included studies and variability in confounder adjustment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HS is associated with a substantial burden of cardiovascular comorbidities and increased risk of several major cardiovascular outcomes. These findings support the consideration of cardiovascular risk assessment in the clinical management of HS while highlighting the need for prospective studies with standardized cardiovascular outcome definitions and more consistent adjustment for key confounders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljag182","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T11:44:19Z","timestamp":1778327059000},"page":"407-420","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular comorbidities and risk in hidradenitis suppurativa: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8237-5176","authenticated-orcid":false,"given":"Sophia A","family":"Mense","sequence":"first","affiliation":[{"name":"Rush University Medical College , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3872-3675","authenticated-orcid":false,"given":"Theresa","family":"Hopkins","sequence":"additional","affiliation":[{"name":"Chicago Medical School, Rosalind Franklin University of Medicine and Science , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-399X","authenticated-orcid":false,"given":"Raj","family":"Chovatiya","sequence":"additional","affiliation":[{"name":"Chicago Medical School, Rosalind Franklin University of Medicine and Science , North Chicago, IL ,","place":["USA"]},{"name":"Center for Medical Dermatology + Immunology Research , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"2026081811173321100_ljag182-B1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0140-6736(24)02475-9","article-title":"Hidradenitis suppurativa","volume":"405","author":"Sabat","year":"2025","journal-title":"Lancet"},{"key":"2026081811173321100_ljag182-B2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2026081811173321100_ljag182-B3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1001\/jamadermatol.2024.3779","article-title":"Genetic susceptibility to hidradenitis suppurativa and predisposition to cardiometabolic disease","volume":"161","author":"Nielsen","year":"2025","journal-title":"JAMA Dermatol"},{"key":"2026081811173321100_ljag182-B4","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/1346-8138.15038","article-title":"Increased risk of cardiovascular comorbidities in hidradenitis suppurativa: a nationwide, population-based, cohort study in Taiwan","volume":"46","author":"Hung","year":"2019","journal-title":"J Dermatol"},{"key":"2026081811173321100_ljag182-B5","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3390\/jcm14041110","article-title":"Hidradenitis suppurativa is associated with an increased risk of adverse cardiac events and all-cause mortality","volume":"14","author":"Rohan","year":"2025","journal-title":"J Clin Med"},{"key":"2026081811173321100_ljag182-B6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/jamadermatol.2015.6264","article-title":"Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa","volume":"152","author":"Egeberg","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2026081811173321100_ljag182-B7","doi-asserted-by":"crossref","first-page":"e70069","DOI":"10.1002\/cbf.70069","article-title":"Th17 cells in cardiovascular disease","volume":"43","author":"Yang","year":"2025","journal-title":"Cell Biochem Funct"},{"key":"2026081811173321100_ljag182-B8","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaci.2022.02.003","article-title":"Insights into hidradenitis suppurativa","volume":"149","author":"van Straalen","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2026081811173321100_ljag182-B9","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1080\/09546634.2021.1959502","article-title":"Hidradenitis suppurativa and association with stroke: systematic review and meta-analysis","volume":"33","author":"Phan","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2026081811173321100_ljag182-B10","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jaad.2014.09.012","article-title":"Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case\u2013control analysis","volume":"71","author":"Shlyankevich","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2026081811173321100_ljag182-B11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jaad.2016.03.025","article-title":"Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa (HS)","volume":"75","author":"Gonz\u00e1lez-L\u00f3pez","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2026081811173321100_ljag182-B12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s13555-018-0264-z","article-title":"The comorbidity burden of hidradenitis suppurativa in the United States: a claims data analysis","volume":"8","author":"Kimball","year":"2018","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026081811173321100_ljag182-B13","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/jdv.15071","article-title":"Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study","volume":"32","author":"Lee","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026081811173321100_ljag182-B14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/jdv.15904","article-title":"Burden, predictors and temporal relationships of comorbidities in patients with hidradenitis suppurativa: a hospital-based cohort study","volume":"34","author":"J\u00f8rgensen","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026081811173321100_ljag182-B15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamadermatol.2019.3412","article-title":"Incidence of myocardial infarction and cerebrovascular accident in patients with hidradenitis suppurativa","volume":"156","author":"Reddy","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2026081811173321100_ljag182-B16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1159\/000513044","article-title":"Implications of hidradenitis suppurativa phenotypes in cardiovascular risk and treatment decisions: a retrospective cohort study","volume":"237","author":"Cuenca-Barrales","year":"2021","journal-title":"Dermatology"},{"key":"2026081811173321100_ljag182-B17","doi-asserted-by":"crossref","first-page":"e151872","DOI":"10.1172\/jci.insight.151872","article-title":"Characterization of comorbidity heterogeneity among 13,667 patients with hidradenitis suppurativa","volume":"6","author":"Hua","year":"2021","journal-title":"JCI Insight"},{"key":"2026081811173321100_ljag182-B18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamadermatol.2021.1570","article-title":"Incidence of venous thromboembolism in patients with dermatologist-diagnosed chronic inflammatory skin diseases","volume":"157","author":"Schneeweiss","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026081811173321100_ljag182-B19","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.jaad.2021.06.864","article-title":"A report of 1290 pediatric hidradenitis suppurativa hospitalizations: a nationwide analysis from the Kids\u2019 Inpatient Database","volume":"86","author":"Edigin","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026081811173321100_ljag182-B20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/ijd.16409","article-title":"Long-term risk of death in patients with hidradenitis suppurativa","volume":"62","author":"Kohorst","year":"2023","journal-title":"Int J Dermatol"},{"key":"2026081811173321100_ljag182-B21","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/jbcr\/irac189","article-title":"Evaluation of outcomes following surgical treatment of hidradenitis suppurativa","volume":"44","author":"Romanowski","year":"2023","journal-title":"J Burn Care Res"},{"key":"2026081811173321100_ljag182-B22","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/ijd.16228","article-title":"Comorbid diseases of hidradenitis suppurativa: a 15-year population-based study in Olmsted County, Minnesota, USA","volume":"61","author":"Sokumbi","year":"2022","journal-title":"Int J Dermatol"},{"key":"2026081811173321100_ljag182-B23","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40257-023-00796-2","article-title":"Disease burden and treatment patterns among US patients with hidradenitis suppurativa: a retrospective cohort study","volume":"24","author":"Garg","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2026081811173321100_ljag182-B24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00403-022-02369-5","article-title":"Hidradenitis suppurativa and the risk of myocardial infarction, cerebrovascular accident, and peripheral vascular disease: a population-based study","volume":"315","author":"Kridin","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"2026081811173321100_ljag182-B25","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/1346-8138.16747","article-title":"Epidemiology and comorbidity of hidradenitis suppurativa in Korea for 17\u2005years: a nationwide population-based cohort study","volume":"50","author":"Lee","year":"2023","journal-title":"J Dermatol"},{"key":"2026081811173321100_ljag182-B26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jdin.2024.10.003","article-title":"Hidradenitis suppurativa is associated with cardiometabolic comorbidities in a racially and ethnically diverse safety net population: a cross-sectional analysis","volume":"18","author":"Alba","year":"2025","journal-title":"JAAD Int"},{"key":"2026081811173321100_ljag182-B27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaad.2024.03.002","article-title":"Association between hidradenitis suppurativa and increased risk of venous thromboembolism: a multicenter retrospective cohort study","volume":"91","author":"Garate","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026081811173321100_ljag182-B28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00403-024-03461-8","article-title":"A marker of systemic inflammation in hidradenitis suppurativa patients without cardiovascular disease: aortic arch calcification","volume":"316","author":"K\u00f6kt\u00fcrk","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"2026081811173321100_ljag182-B29","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/ijd.17186","article-title":"Risk of cardiovascular disorders in hidradenitis suppurativa patients: a large-scale, propensity-matched global retrospective cohort study","volume":"63","author":"Krajewski","year":"2024","journal-title":"Int J Dermatol"},{"key":"2026081811173321100_ljag182-B30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/fampra\/cmae037","article-title":"Epidemiology and clinical correlates of hidradenitis suppurativa in primary care in Italy","volume":"41","author":"Lapi","year":"2024","journal-title":"Fam Pract"},{"key":"2026081811173321100_ljag182-B31","doi-asserted-by":"crossref","first-page":"1499509","DOI":"10.3389\/fmed.2024.1499509","article-title":"Demographic features, clinical characteristics, and comorbid relation in hidradenitis suppurativa: a population-based study","volume":"11","author":"Kaya","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2026081811173321100_ljag182-B32","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1186\/s12872-025-05139-z","article-title":"Trends and sociodemographic disparities in the circulatory disease prevalence in the United States: an analysis of the National Health Interview Survey database (2019\u20132022)","volume":"25","author":"Yasmin","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"2026081811173321100_ljag182-B33","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of Patients With Chronic Coronary Disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"2026081811173321100_ljag182-B34","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/1346-8138.16484","article-title":"Biomarkers of endothelial dysfunction and atherosclerosis in hidradenitis suppurativa","volume":"49","author":"Gonz\u00e1lez-L\u00f3pez","year":"2022","journal-title":"J Dermatol"},{"key":"2026081811173321100_ljag182-B35","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjd.19556","article-title":"Aetiology and pathogenesis of hidradenitis suppurativa","volume":"183","author":"Wolk","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026081811173321100_ljag182-B36","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/jdv.20472","article-title":"European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: Treatment","volume":"39","author":"Zouboulis","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag182\/68268737\/ljag182.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/195\/3\/407\/68268737\/ljag182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/195\/3\/407\/68268737\/ljag182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:23:32Z","timestamp":1787066612000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/195\/3\/407\/8675971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5,11]]},"published-print":{"date-parts":[[2026,8,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljag182","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,5,11]]}}}